v3.26.3
Discontinued Operations - Schedule of Details of Loss from Discontinued Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jan. 30, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Revenue [1]       $ (29,285)  
Income tax benefit (expense) $ (39,200)        
Income (loss) from discontinued operations, net of tax   $ 28,460 $ (3,003) 164,921 $ (21,452)
SomaScan Business          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Revenue [2]   0 26,693 37,172 67,466
Cost of revenue   0 14,352 4,504 37,784
Selling, general and administrative expenses   0 8,474 6,055 25,573
Research and development   0 4,849 2,881 16,587
Transaction expenses   0 2,203 15,237 12,710
Total operating costs and expenses   0 29,878 28,677 92,654
Operating income (loss)   0 (3,185) 8,495 (25,188)
Other income, net   0 181 131 3,578
Gain on sale of business   29,989 0 202,278 0
Indemnification-related loss [3]   0 0 (4,212) 0
Income (loss) from discontinued operations before income taxes   29,989 (3,004) 206,692 (21,610)
Income tax benefit (expense)   (1,529) 1 (41,771) 158
Income (loss) from discontinued operations, net of tax   $ 28,460 $ (3,003) $ 164,921 $ (21,452)
[1] Deferred revenue related to the Collaboration Agreement with Illumina was fully recognized upon the sale of the Disposed Entities. The Company has classified this revenue within discontinued operations consistent with the treatment of all SomaScan Business-related activities. Please see Note 3, Discontinued Operations, for more information.
[2] During the nine months ended September 30, 2026, the Company recognized revenue of $29.8 million related to the transaction price under the Collaboration Agreement with Illumina, which primarily reflects the release of the deferred revenue balance previously established under the Collaboration Agreement upon the sale of the SomaScan Business. The Company has classified the $29.8 million within discontinued operations consistent with the treatment of all SomaScan Business-related activities. Out of the $29.8 million recognized, $0.6 million reflects Illumina’s exercise of its material right to be provided with SOMAmer reagents for commercialization of the co-branded kits.
[3] In connection with the sale of SomaLogic to Illumina, the Company agreed to indemnify Illumina for certain litigation matters. The Company recorded a liability of $3.3 million as of the closing date, which remained unchanged as of March 31, 2026. During the three months ended June 30, 2026, the Company recorded an additional charge of $4.2 million related to the litigation matters, which were settled in July 2026. The Company paid $7.5 million in July 2026 in full settlement of these matters, and no indemnification liability remained as of September 30, 2026.